Long-term carvedilol therapy in patients with stage II arterial hypertension
In total, 30 patients with Stage II arterial hypertension, AH (ESH/ESC 2003; Society of Cardiology of the Russian Federation 2004), mean age 51. 93 ± 7.96years. For 6 months, participants received carvedilol (Talliton, Hungary, Egis) in daily dose 25-75 mg. Microcirculation, hemorheology, and lipid...
Main Authors: | , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2006-06-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1841 |
id |
doaj-e48086fa95d74d90988f46fe445f7a05 |
---|---|
record_format |
Article |
spelling |
doaj-e48086fa95d74d90988f46fe445f7a052021-07-28T14:02:08Zrus«FIRMA «SILICEA» LLC Российский кардиологический журнал1560-40712618-76202006-06-010363661602Long-term carvedilol therapy in patients with stage II arterial hypertensionL. I. Markova0A. E. Radzevich1Московский государственный медикоFстоматологический университет, кафедра терапии №1 факультета постдипломного образованияМосковский государственный медикоFстоматологический университет, кафедра терапии №1 факультета постдипломного образованияIn total, 30 patients with Stage II arterial hypertension, AH (ESH/ESC 2003; Society of Cardiology of the Russian Federation 2004), mean age 51. 93 ± 7.96years. For 6 months, participants received carvedilol (Talliton, Hungary, Egis) in daily dose 25-75 mg. Microcirculation, hemorheology, and lipid profile were assessed at baseline and after treatment, by conjunctival biomicroscopy and laboratory tests. Carvedilol corrected microcirculation due to its effects on vessels and capillaries, long-term carvedilol treatment didn't affected blood lipid profile, and beneficially influenced hemorheologyhttps://russjcardiol.elpub.ru/jour/article/view/1841carvedilolarterial hypertensionmicrocirculationblood lipid profilehemorheology |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
L. I. Markova A. E. Radzevich |
spellingShingle |
L. I. Markova A. E. Radzevich Long-term carvedilol therapy in patients with stage II arterial hypertension Российский кардиологический журнал carvedilol arterial hypertension microcirculation blood lipid profile hemorheology |
author_facet |
L. I. Markova A. E. Radzevich |
author_sort |
L. I. Markova |
title |
Long-term carvedilol therapy in patients with stage II arterial hypertension |
title_short |
Long-term carvedilol therapy in patients with stage II arterial hypertension |
title_full |
Long-term carvedilol therapy in patients with stage II arterial hypertension |
title_fullStr |
Long-term carvedilol therapy in patients with stage II arterial hypertension |
title_full_unstemmed |
Long-term carvedilol therapy in patients with stage II arterial hypertension |
title_sort |
long-term carvedilol therapy in patients with stage ii arterial hypertension |
publisher |
«FIRMA «SILICEA» LLC |
series |
Российский кардиологический журнал |
issn |
1560-4071 2618-7620 |
publishDate |
2006-06-01 |
description |
In total, 30 patients with Stage II arterial hypertension, AH (ESH/ESC 2003; Society of Cardiology of the Russian Federation 2004), mean age 51. 93 ± 7.96years. For 6 months, participants received carvedilol (Talliton, Hungary, Egis) in daily dose 25-75 mg. Microcirculation, hemorheology, and lipid profile were assessed at baseline and after treatment, by conjunctival biomicroscopy and laboratory tests. Carvedilol corrected microcirculation due to its effects on vessels and capillaries, long-term carvedilol treatment didn't affected blood lipid profile, and beneficially influenced hemorheology |
topic |
carvedilol arterial hypertension microcirculation blood lipid profile hemorheology |
url |
https://russjcardiol.elpub.ru/jour/article/view/1841 |
work_keys_str_mv |
AT limarkova longtermcarvediloltherapyinpatientswithstageiiarterialhypertension AT aeradzevich longtermcarvediloltherapyinpatientswithstageiiarterialhypertension |
_version_ |
1721269715507085312 |